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Purpose/Objective: To evaluate feasibility in a multicentric 
setting and clinical results of a RT boost for children with 
Ependymoma and measurable residual disease after first line 
or second look surgery. 
Materials and Methods: The second AIEOP (Italian 
Association of Pediatric Hematology and Oncology) protocol 
for childhood ependymoma opened in 2003. After centralized 
pathological review, children were stratified to receive: 1) 
3D conformal RT or IMRT, 59.4 Gy/33 fractions, to the tumor 
bed in case of complete resection and grade II tumor; 2) 
same RT followed by four cycles of VEC chemotherapy in case 
of complete resection and anaplastic ependymoma; 3) VECx4, 
second look surgery whenever feasible, local RT as in 1) 
followed by a stereotactic hypofractionated (8 Gy/2 
fractions) boost to the residue still measurable after previous 
treatments. 
Results: From 2003, 143 children entered the study (median 
follow-up 60 months). In 24 children (median age 4,5 years, 
15 grade II, 20 infratentorial), out of 46 with residue after 
first surgery, second look wasn't feasible or incomplete and 
thus received VEC and 59.4 Gy to the tumor bed plus 8 Gy to 
the gross residue. 15/24 children are alive without 
progression at a median of 51 months (range 11-120 mos) 
from diagnosis, 5/6 died of local progression at a median of 
20 months, and 3 relapsed distantly, 17-23 months from 
diagnosis, and have died. No iatrogenic death or major 
toxicity occurred. 4 children, irradiated with Tomotherapy, 
developed radiation related MRI changes regressing with 
steroids within 8 months. In the 46 children with residual 
disease, 3 and 5 years PFS was 64% and 55%, and OS 80% and 
68% respectively. 3 and 5-year survival free from local 
relapse was 71% and 64% respectively. 5 year-EFS for children 
receiving the RT boost was 57%. 
Conclusions: Hypofractionated RT boost was feasible and 
contributed to obtain durable local control in 15/24 children 
with measurable residue after first line or second look 
surgery. An aggressive and integrated local treatment 
strategy, multiple surgeries and RT including an 
hypofractionated boost in case of residual disease, is 
required to improve outcome in children with Ependymoma. 
This background will be the basis of the next opening SIOP 
(Société International d'Oncologie Pediatrique) trial for 
Ependymoma.  
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Stereotactic body radiotherapy (SBRT) frequently involves the 
accurate delivery of a few large fractions to a relatively well-
defined target. The favorable anti-tumor characteristics of 
large fractions needs to be balanced against the fact that 
they are often poorly tolerated by normal organs. Although 
this means that SBRT is not possible in all clinical situations, 
in others the risks can be managed in a variety of ways 
including the use of planning and delivery techniques that 
simultaneously facilitate target coverage and organ at risk 
sparing. While the application of extremely hypo-
fractionated radiotherapy to the radical treatment of primary 
tumors is not new, current interest coincides with the 
widespread availability of advanced radiotherapy systems. 
Nonetheless, the successful paradigm of using SBRT to treat 
peripheral, early-stage lung cancer has yet to be replicated 
in other clinical scenarios. Against this background the 
present talk aims to briefly outline the essential features of 
SBRT; describe the historical aspects of extreme hypo-
fractionation for radical treatments; succinctly review the 
current literature on SBRT for treating primary tumors; 
discuss some of the challenges in using SBRT for this 
indication; and touch on future perspectives. 
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Metastases account for approximately 80–90% of cancer 
deaths. Systemic therapies (either cytotoxic chemotherapy or 
targeted agents), the cornerstone for treatment in 
metastatic disease, are rather than curative. Therefore, 
novel therapies for the treatment of patients with metastatic 
cancer are needed. 
In 1995, Hellmann and Weichselbaum coined the term 
“oligometastases” to describe a less-advanced (or 
“intermediate”) state of metastatic disease, peculiarly 
situated between locoregionally-confined and widely-
metastatic cancer. In this paradigm, a limited burden of 
metastatic disease may be amenable to potentially curative 
local therapies.  
Stereotactic Body RadioTherapy (SBRT), which is also 
referred to as Stereotactic Ablative Radiotherapy (SABR), is a 
form of high-precision radiotherapy, tipically delivered in one 
to 8 fractions, commonly using fraction sizes of 7.5 Gy or 
more. SBRT allows for target dose-escalation (thus increasing 
tumor control), while minimizing normal tissue exposure 
(thus minimizing the toxicity risk). When compared to 
surgery, SBRT has the theoretical advantage to be less 
invasive and more effective, because of  lower morbidity 
rates, lower costs and the potential for delivering ablative 
treatments on an outpatient basis. 
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A compelling body of non-randomized evidence has showed 
that SBRT is a safe and efficient way to control multiple 
metastatic sites. However, when treating metastatic patients 
(even if “oligometastatic”), selection criteria are a pivotal 
issue. In general, clinical indications are the same as those 
for metastasectomy (pulmonary and/or liver 
metastasectomy), but without the limits regarding patients 
unfit for surgery. 
Current literature has showed promising long-term survival 
outcomes after SBRT for limited metastases. Future studies 
are, and will be, addressing: 1) what (if any) benefit SBRT 
(and other local therapies) should offer for patients with 
limited metastases, 2) which patients are most likely to 
benefit from SBRT (host-related factors underlying the 
oligometastatic state, i.e. miRNA), 3) optimal dose and 
fractionation schedules, 4) what radiobiologic mechanisms 
are relevant in the treatment of the target tumor (i.e., SBRT 
as “immunomodulator”). 
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Standard treatment of metastatic cancer is systemic 
therapies. Local treatments for oligometastatic patients may 
have significant role since a large majority of patients 
treated with systemic chemotherapy experience progression 
mostly in initial sites of tumor burden rather than new sites 
of progression. Surgical excision of metastatic sites usually 
from liver and lung that have been shown to prolong survival 
in colorectal cancer, sarcomas, melanoma, breast cancer and 
many other tumor types.  
Currently surgery is considered to be standard approach for 
these groups of patients. Surgical series of hepatic 
metastasectomy of primary colorectal cancer resulted 18-51 
% 5-year survival rate with 2-7% operative mortality and 6-13 
% serious morbidity risk. Most of the metastasectomy data 
are based on single institutional series and had many 
confounding factors such as patient selection that cause 
some doubts about the results. It should also be considered 
that many tumors are inoperable due to tumor location or 
medical inoperability of the patient. 
Stereotactic treatment was developed by a neurosurgeon Lars 
Leksell to treat inoperable deeply seated lesions in the brain. 
SABR recently become popular to extra-cranial sites with 
technological improvements. Its strengths include high rates 
of tumor eradication via non-invasive, convenient, short 
outpatient treatment course, favorable toxicity and no 
recovery time. It yielded very good results for treatment of 
primary and metastatic tumors in various body sites in 
properly selected patients. However despite potential 
advantages, there are few published retrospective or phase II 
studies with limited patient number. These studies about 
metastatic liver disease that have been treated with SABR 
yielded 70-82 % 2-year local control rate without any serious 
toxicity. So there is great hope that SABR may find prominent 
place in treatment of metastatic cancer. There are also few 
literature data with favorable results on lung, adrenal, lymph 
node metastasis treated with SABR. 
There is no randomized study comparing efficacy and toxicity 
of surgery and SABR in oligometastatic setting. Many authors 
consider surgery as the standard treatment for local 
management of metastatic sites. However, SABR is promising 
approach as a complementary or alternative regimen to 
surgery. Until well-designed randomized studies comparing 
these two regimens, selection of treatment should be 
individualized to the patient with the guidance of available 
data. 
Individualization of treatment is dependent on patient 
factors and metastatic sites. Performance status, 
comorbidities of the patient, location and number of 
metastatic sites, previous treatments, underlying prognosis, 
tumor biology and experience of the team are all important 
factors for consideration of local treatment.  
   
OC-0314   
Can SBRT be a viable therapeutic option for unresectable 
pancreatic adenocarcinoma? Results of phase II study 
T. Comito1, E. Clerici1, G.R. D'Agostino1, P. Navarria1, A. 
Tozzi1, C. Iftode1, C. Franzese1, E. Villa1, F. De Rose1, A.M. 
Ascolese1, F. Lobefalo1, A. Zerbi2, L. Rimassa3, C. Carnaghi3, 
M.C. Tronconi3, M. Scorsetti1 
1Istituto Clinico Humanitas, Radiotherapy and Radiosurgey, 
Rozzano (Milan), Italy  
2Istituto Clinico Humanitas, Pancreatic Surgery, Rozzano 
(Milan), Italy  
3Istituto Clinico Humanitas, Oncology, Rozzano (Milan), Italy  
 
Purpose/Objective: To assess the safety and efficacy of 
stereotactic body radiotherapy (SBRT) in patients affected by 
inoperable locally advanced pancreatic adenocarcinoma and 
local recurrence after surgery. 
Materials and Methods: Patients with unresectable locally 
advanced tumor or local recurrence disease were treated 
with exclusive SBRT. All cases were evaluated by 
multidisciplinary team. Irradiated lesions had a diameter less 
than 5 cm and no metastatic disease was present at the time 
of SBRT. Prescription dose was 45 Gy in 6 daily fractions of 
7.5 Gy. SBRT was delivered using the volumetric modulated 
arc therapy (VMAT) by RapidArc technique. Primary end-point 
was freedom from local progressions (FFLP) and secondary 
end-points were overall survival (OS) and toxicity. Local 
control was defined according to RECIST criteria. Acute and 
late toxicity was scored according to the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0. 
Results: Between January 2010 and October 2012, 62 
patients were treated. Forty five patients (74%) had 
unresectable locally advanced disease and 17 patients (26%) 
had local recurrence after surgery. Median follow-up was 12 
months (3 – 48 months). Nineteen (30%) patients were alive 
at the time of analysis. Median follow-up was 17 months in 
this group of patients (range 12–48 months). In patients with 
inoperable locally advanced disease, FFLP was 90% at 1year. 
Median progression free-survival was 8 months. Median OS 
was 13 months, with 1-year OS rate of 51%. Ca 19.9 value 
increased in 28 cases (62% of this subgroup) and Ca 19.9 
value was less than 300 U/ml in 12 patients (43%) while it 
was more than 300 U/ml in 16 patients (57%). Univariate 
analysis showed that Ca 19.9 < 300 U/ml was closely 
correlated (p = .055) to a better OS. In those patients with 
local recurrence after surgery, FFLP was 85% at median 
follow-up. Median progression free-survival was 9 months. 
Median OS was 19 months, with 1-year OS rate of 53%. In all 
the cases, toxicity rates were satisfactory with no patients 
who experienced acute grade 3 toxicity or greater. 
Conclusions: SBRT is a safe and efficacy treatment to 
improve local control in patients with unresectable locally 
advanced or recurrence pancreatic adenocarcinoma, in 
absence of grade 3 toxicity or greater. Our results suggest 
that SBRT may be a promising therapeutic option in the 
multi-modality treatment of these patients.  
   
OC-0315   
